doxepin

(redirected from Silenor)
Also found in: Thesaurus, Medical.
Related to Silenor: doxepin

dox·e·pin

 (dŏk′sə-pĭn′)
n.
A tricyclic drug, C19H21NO, used in its hydrochloride form orally to treat depression and anxiety and as a cream to relieve itching.

[d(ibenz)oxepin(e), tricyclic structural constituent : di- + benz- + oxepin(e), seven-member ring with one oxygen atom (ox(o)- + (h)ep(ta)- + -ine).]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.doxepin  - a tricyclic antidepressant (trade names Adapin and Sinequan) with numerous side effects (dry mouth and sedation and gastrointestinal disturbances)doxepin - a tricyclic antidepressant (trade names Adapin and Sinequan) with numerous side effects (dry mouth and sedation and gastrointestinal disturbances)
tricyclic, tricyclic antidepressant, tricyclic antidepressant drug - an antidepressant drug that acts by blocking the reuptake of norepinephrine and serotonin and thus making more of those substances available to act on receptors in the brain
References in periodicals archive ?
Silenor TRx up 4% in the third quarter of 2017 as compared to the second quarter, and were flat year-over-year.
Pernix added that the deal brings the company a unique product franchise at early stages of launch, with an attractive competitive environment, and is an excellent strategic fit with the company's CNS focus, providing immediate sales synergies in a previously untapped market segment for Silenor.
Recently, the drug doxepin (Silenor) was approved for the treatment of insomnia.
M2 PHARMA-May 2, 2013-Paladin Labs Inc announces availibility of insomnia drug Silenor in Canada(C)2013 M2 COMMUNICATIONS
The tricyclic antidepressant doxepin (Silenor) was approved for insomnia in 2010 at 3-mg and 6-mg doses, but it cannot be used with monoamine oxidase inhibitors.
New medications, including doxepin (Silenor) 3 to 6 mg, Lunesta in tapering doses 3-2-1 mg, Rozerem 8 mg, and Saphris (for anxiety stabilization and sleep effect), are quite useful in stabilizing individuals.
Doxepin (Silenor), a drug that was initially developed to treat depression, was approved by the FDA last year for treatment of insomnia characterized by waking frequently or waking too early and not being able to return to sleep.
The approval earlier this month of Somaxon's Silenor (doxepin) for insomnia characterized by trouble staying asleep, means a second nonscheduled insomnia medication will enter the market.
Food and Drug Administration for its histamine-blocking drug Silenor as a sleep aid.
"During the first quarter of 2009 we continued to focus on our key corporate objectives, notably to gain regulatory approval for Silenor, to secure a commercial partnership for Silenor and to improve our financial outlook," said Richard W.
M2 EQUITYBITES-May 2, 2013-Paladin Labs Inc announces availibility of insomnia drug Silenor in Canada(C)2013 M2 COMMUNICATIONS http://www.m2.com